GlobeNewswire

The results of the private placement of Subordinated Convertible Notes and private placement of Secured Notes of AS PRFoods / transactions with persons connected with the issuer

Share

THIS NOTICE IS NOT INTENDED FOR PUBLICATION, ALLOCATION OR TRANSMISSION, IN PART OR WHOLLY, DIRECTLY OR INDIRECTLY, IN THE UNITED STATES, AUSTRALIA, CANADA, HONG KONG, JAPAN, NEW ZEALAND, SINGAPORE, SOUTH AFRICA, OR ELSEWHERE THE DISCLOSURE OR TRANSMISSION OF THIS INFORMATION IS NOT ALLOWED.

By a company announcement dated 04.06.2021, AS PRFoods (hereinafter "PRFoods") informed investors that it was conducting an issue of subordinated convertible notes, whereunder PRFoods is to issue up to 350 subordinated convertible notes, with the maximum aggregate nominal value of up to EUR 3,500,000, nominal value of EUR 10,000 per subordinated convertible note, interest rate of 7% per annum and maturity date on 01.10.2025 (hereinafter the “ConvertibleNotes”).

The subscription period for the Convertible Notes ended on 14.06.2021. In course of the private placement, investors subscribed for 237 Convertible Notes, with the aggregate nominal value of EUR 2,370,000, i.e. for approximately 67% of the maximum volume of the placement. As a result of the placement, PRFoods decided to allocate to investors a total of 237 Convertible Notes, with the aggregate nominal value of EUR 2,370,000. PRFoods intends to issue the Convertible Notes which were allocated to investors by the placement on or around 22.06.2021, after the payment of the subscription price for the Convertible Notes by the investors.

PRFoods hereby informs that among other investors also the shareholders of PRFoods Amber Trust II S.C.A., SICAR (hereinafter “Amber Trust”), KJK Fund SICAV-SIF (hereinafter “KJK”) and Lindermann, Birnbaum & Kasela OÜ (hereinafter “LBK OÜ”) submitted subscription undertakings in course of the placement by subscribing for a total of 217 Convertible Notes with the aggregate nominal value of EUR 2,170,000. The shareholders subscribed for the Convertible Notes under uniform terms and conditions applicable with respect to all investors having participated in the private placement of the Convertible Notes. As a result of the subscription, PRFoods allocated to its shareholder Amber Trust 171 Convertible Notes with the aggregate nominal value of 1,710,000 EUR, which issue price will be paid by Amber Trust by way of set-off of its claim arising from the EUR 1,000,000 loan agreement entered into with PRFoods on 01.03.2021 and partial set-off of its claim arising from the EUR 1,500,000 loan agreement dated 14.07.2017. 36 and 10 Convertible Notes with respective aggregate nominal value of EUR 360,000 and EUR 100,000 were allocated by PRFoods to KJK and LBK OÜ respectively, the issue price of which will be paid by the referred shareholders by way of cash payment in accordance with the terms and conditions of the Notes dated 24.05.2021 and final terms dated 04.06.2021.

In addition, PRFoods informed investors by a company announcement dated 07.05.2021 (as corrected by the correction announcement dated 18.05.2021) that it was planning a tap-issue of notes bearing ISIN code EE3300001577 (the “Secured Notes”), issued under the Terms and Conditions of Secured Note Issue of PRFoods dated 14.01.2020 (as amended on 25.02.2020), in the amount of up to EUR 1,000,000.

In accordance with the resolutions of the supervisory board of PRFoods dated 14.05.201, the management board of PRFoods decided, under its resolutions dated 10.06.2021, to conduct a targeted placement of Secured Notes to its shareholder Amber Trust. The subscription period for the Secured Notes ended on 14.06.2021 and, as a result thereof, Amber Trust subscribed to all of the 10,000 Secured Notes offered under the targeted private placement with the nominal value of EUR 100 per Secured Note, maturity date of 22.01.2025, early redemption rights and fixed interest rate of 6.25% per calendar year. Other than as brought out herein, the material terms and conditions of the Secured Notes are as described in the company announcement dated 07.05.2021 (as corrected by the correction announcement dated 18.05.2021). The subscription price for the Secured Notes – designated to be EUR 100.25 per Secured Note by the management of PRFoods – will be fully paid by Amber Trust prior to the issue of the Secured Notes by way of setting off the respective issue price against the claim of outstanding principal and part of the interest under the EUR 1,500,000 loan agreement entered into with PRFoods on 14.07.2017.

As in accordance with the securities market act, Amber Trust and KJK have a qualified holding in PRFoods and LBK OÜ constitutes a company connected with Indrek Kasela, the subscription by Amber Trust, KJK and LBK OÜ to the Convertible Notes, the subscription by Amber Trust to the Secured Notes, and the resulting issue of the notes thereto, as well as the described transactions of set-off qualify as transactions entered into with persons connected to the issue under the rules “Requirements for Issuers” of Nasdaq Tallinn Stock Exchange.

PRFoods is advised by Advokaadibüroo COBALT OÜ on legal aspects and by Redgate Capital AS on financial matters relating to the private placement and issue of the Notes.

Important information:

This announcement is not to be construed as an offer or solicitation for the purchase of the Notes, nor shall the sale or offer of the Notes take place in any jurisdiction where such offer, invitation or sale would be unlawful without the exception or qualification of law, prior to the registration of the prospectus.

The information contained in this notice is not intended to be published, distributed or transmitted, in whole or in part, directly or indirectly, in the United States, Australia, Canada, Hong Kong, Japan, New Zealand, Singapore, South Africa, or in any other country or circumstance where publication, sharing or transmission would be unlawful.


Additional information:

Indrek Kasela
AS PRFoods
Member of the Management Board
+372 452 1470
investor@prfoods.ee
www.prfoods.ee

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire

GlobeNewswire
GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://globenewswire.com

GlobeNewswire is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire

Subscribe to all the latest releases from GlobeNewswire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire

Boyden Welcomes Healthcare & Life Sciences Expert Stephen Irish as Managing Partner, Japan4.8.2021 20:00:00 CEST | Press release

Long-term specialist in senior-level recruitment in Japan and Asia/Pacific joins Boyden as head of the Japan office and member of Boyden’s global healthcare & life sciences practice TOKYO, Aug. 04, 2021 (GLOBE NEWSWIRE) -- Boyden, a premier leadership and talent advisory firm with more than 75 offices in over 45 countries, is delighted to welcome Stephen Irish as Managing Partner and head of Boyden Japan. Based in Tokyo, Irish joins Boyden’s global healthcare & life sciences practice, leading senior level searches for clients in Japan and Asia/Pacific, as well as those headquartered outside the region. “Japan is a unique market, and requires specialist knowledge and understanding of the cultural nuances at the individual, organisational and government level,” commented Stephen Irish, Managing Partner, Boyden Japan. “Having worked with Japanese companies throughout my career, I am delighted to bring this experience into a collaborative, international environment with Boyden. For clients

Novo Nordisk's net profit increased by 10% in the first six months of 20214.8.2021 16:41:41 CEST | Press release

4 August 2021 - Financial report for the period 1 January 2021 to 30 June 2021 Operating profit decreased by 1% in Danish kroner and increased by 9% at constant exchange rates (CER).Sales increased by 5% in Danish kroner and by 12% at CER to DKK 66.8 billion. Sales in International Operations increased by 7% in Danish kroner (13% at CER), and sales in North America Operations increased by 1% in Danish kroner (11% at CER).Sales within Diabetes and Obesity care increased by 5% in Danish kroner to DKK 56.9 billion (13% at CER), driven by GLP-1 growth of 21% in Danish kroner (30% at CER) reflecting the uptake of Ozempic® and Rybelsus®. Obesity care grew by 23% in Danish kroner (34% at CER) and Biopharm sales remained unchanged in Danish kroner (increased by 7% at CER).In June 2021, Wegovy™, semaglutide 2.4 mg, was made available to patients in the US following the approval from the US Food and Drug Administration (FDA) for weight management in adults living with obesity.For the 2021 outloo

Novo Nordisk's net profit increased by 10% in the first six months of 20214.8.2021 16:23:58 CEST | Press release

4 August 2021 - Financial report for the period 1 January 2021 to 30 June 2021 Operating profit decreased by 1% in Danish kroner and increased by 9% at constant exchange rates (CER).Sales increased by 5% in Danish kroner and by 12% at CER to DKK 66.8 billion. Sales in International Operations increased by 7% in Danish kroner (13% at CER), and sales in North America Operations increased by 1% in Danish kroner (11% at CER).Sales within Diabetes and Obesity care increased by 5% in Danish kroner to DKK 56.9 billion (13% at CER), driven by GLP-1 growth of 21% in Danish kroner (30% at CER) reflecting the uptake of Ozempic® and Rybelsus®. Obesity care grew by 23% in Danish kroner (34% at CER) and Biopharm sales remained unchanged in Danish kroner (increased by 7% at CER).In June 2021, Wegovy™, semaglutide 2.4 mg, was made available to patients in the US following the approval from the US Food and Drug Administration (FDA) for weight management in adults living with obesity.For the 2021 outloo

Nexstim to Exhibit at the Texas Association of Neurological Surgeons Annual Meeting4.8.2021 15:00:00 CEST | Press release

Press release, Helsinki, 4 August 2021 at 4 PM(EEST) Nexstim to Exhibit at the Texas Association of Neurological Surgeons Annual Meeting Nexstim Plc (NXTMH:HEX, NXTMS:STO) ("Nexstim" or "Company") announces that it will be exhibiting during the annual meeting of the Texas Association of Neurological Surgeons this week, August 5-8, 2021 at the Hyatt Regency Lost Pines Resort & Spa in Lost Pines, Texas. This meeting continues to be a significant opportunity for Nexstim to engage current and prospective users of the Nexstim system. Further information is available on the website www.nexstim.com, or by contacting: Mikko Karvinen, CEO +358 50 326 4101 mikko.karvinen@nexstim.com About Nexstim Plc Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable personalized and effective therapies and diagnostics for challenging brain diseases and disorders. Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a

ProMIS Neurosciences Issues Chairman’s Memorandum4.8.2021 13:30:00 CEST | Press release

Notes and comments after the first AAIC meeting in the era of approved disease-modifying therapies for Alzheimer’s Disease TORONTO and CAMBRIDGE, Mass., Aug. 04, 2021 (GLOBE NEWSWIRE) -- ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics targeting toxic oligomers implicated in the development of neurodegenerative diseases, issued today a Chairman’s memorandum, commenting on highlights of the recent 2021 Alzheimer’s Association International Conference (AAIC) with relevance to ProMIS and summarizing the ProMIS poster/oral presentation contributions to the meeting. “We are in a new era in the fight against Alzheimer’s, ALS, and other neurodegenerative diseases,” stated Eugene Williams, Executive Chairman of ProMIS Neurosciences. “ProMIS and many others have predicted this development and we believe that the Alzheimer’s community will look back on 2021 as a turning point, just as 2010 was a turnin

Aspo Plc will publish its Half year financial report on August 11, 20214.8.2021 12:00:00 CEST | Press release

Aspo Plc Press Release August 4, 2021 at 1 p.m. Aspo Plc will publish its Half year financial report on August 11, 2021 Aspo Plc will publish its Half year financial report for January–June 2021 on Wednesday, August 11, 2021 at approximately 9:30 a.m. EEST. The press conference for analysts, investors and media will be held on Wednesday, August 11, 2021 at 2 p.m. The Half year financial report will be presented by CEO Aki Ojanen. The press conference will be held in Finnish and it can be followed at https://aspo.videosync.fi/2021-q2-results, or by calling +358 9 817 10310 (12219443#) 5 to 10 minutes before the beginning of the press conference. The recording of the event will be available on the company’s website later on the same day. Presentation material will be available at www.aspo.com before the event. Aspo Plc Aki Ojanen CEO For further information, please contact: Keijo Keränen, Group Treasurer, +358 400 955 821, keijo.keranen@aspo.com DISTRIBUTION: Key media www.aspo.com Aspo

Cortus Energy: Sista dag för handel med betalda tecknade units (BTU) och omvandling till aktier och teckningsoptioner av serie TO8 och TO94.8.2021 09:46:34 CEST | Pressemelding

PRESSMEDDELANDE Stockholm, den 4 augusti 2021 Cortus Energy AB (”Cortus Energy” eller ”Bolaget”) har som tidigare kommunicerats genomfört en övertecknad företrädesemission av units om cirka 64,8 MSEK ("Företrädesemissionen"). Företrädesemissionen är nu registrerad hos Bolagsverket ochsista dag för handel med BTU är fredagenden 6augusti 2021. Avstämningsdag för omvandlingen är den 10augusti 2021, varefter BTU kommer att omvandlas till aktier och teckningsoptioner av serie TO8 och TO9. Aktier och teckningsoptioner som tecknades i Företrädesemissionen förväntas vara tillgängliga på tecknarens depå/vp-konto den 12 augusti 2021. Första handelsdag för teckningsoptionerna i serie TO8 och TO9 förväntas vara den 13 augusti 2021. Teckningsoptioner av serie TO8 Teckning av aktier med stöd av teckningsoptioner av serie TO8 sker under perioden från och med den 16 november 2021 till och med den 29 november 2021. Varje teckningsoption av serie TO8 ger rätt att teckna en (1) ny aktie i Bolaget mot kon